Sectors

GDTC
CytoMed Therapeutics Limited
0.96
1 x 1.00
120 x 1.26
bid
ask
-
0.01
1.03%
04:00 PM
timesize
Ytd-28.36%
1y-52.48%
0.96
day range
0.96
0.68
52 week range
3.68
Open0.96Prev Close0.97Low0.96High0.96Mkt Cap11.48M
Vol173.00Avg Vol18.84KEPS-0.22P/E-4.49Forward P/E-15.80
Beta0.01Short Ratio7.54Inst. Own0.04%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning04-2850-d Avg1.06200-d Avg1.321yr Est5.00

GDTC News

9 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
9 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

Why Align Technology Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Align Technology Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

CytoMed Therapeutics (NASDAQ:GDTC)  Shares Down 11%   – Here’s What Happened
defenseworld.net
CytoMed Therapeutics (NASDAQ:GDTC) Shares Down 11% – Here’s What Happened

CytoMed Therapeutics Limited (NASDAQ: GDTC - Get Free Report)'s stock price dropped 11% during tradi

12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session

CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 7.2%  – Here’s Why
defenseworld.net
CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 7.2% – Here’s Why

CytoMed Therapeutics Limited (NASDAQ: GDTC - Get Free Report)'s stock price was up 7.2% on Thursday.

CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript
seekingalpha.com
CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript

CytoMed Therapeutics Limited (NASDAQ:GDTC ) Q2 2025 Earnings Call October 2, 2025 10:00 AM EDT Compa

CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
globenewswire.com
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, M

SINGAPORE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed”

Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
globenewswire.com
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on it

SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed”

CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
globenewswire.com
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program

SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed”

benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
globenewswire.com
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on Novemb

CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
globenewswire.com
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinic

SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed”

CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders
globenewswire.com
CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders

SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed”

Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor
benzinga.com
Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor

On Monday, CytoMed Therapeutics GDTC stock is down 6.35% at $3.23 at last check Monday.

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
globenewswire.com
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allo

Another Patent Granted for CytoMed's Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybri

CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration
accesswire.com
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkan

SINGAPORE / ACCESSWIRE / March 20, 2024 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
globenewswire.com
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Prec

SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed”

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
globenewswire.com
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospit

SINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed”

Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
globenewswire.com
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Techno

The Company now has exclusive rights to a Malaysia, US and China patent The Company now has exclusiv

CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
prnewswire.com
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technolo

SINGAPORE , Dec. 5, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update
prnewswire.com
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update

Conference call webcast is scheduled for November 22 at 9 a.m. ET. SINGAPORE , Nov. 17, 2023 /PRNews

CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
prnewswire.com
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Co

SINGAPORE , Nov. 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or

CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology
accesswire.com
CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licens

SINGAPORE / ACCESSWIRE / October 24, 2023 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or

Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology
prnewswire.com
Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology

SINGAPORE , Sept. 25, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or